Iteos Other Operating Expenses from 2010 to 2025
| ITOS Stock | USD 7.07 0.09 1.29% |
Other Operating Expenses | First Reported 2019-03-31 | Previous Quarter 49.2 M | Current Value 48.8 M | Quarterly Volatility 15.7 M |
Check Iteos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iteos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 3.9 M, Net Interest Income of 37.3 M or Interest Income of 37.3 M, as well as many indicators such as Price To Sales Ratio of 29.38, Dividend Yield of 0.0 or PTB Ratio of 0.74. Iteos financial statements analysis is a perfect complement when working with Iteos Therapeutics Valuation or Volatility modules.
Iteos | Other Operating Expenses |
Latest Iteos Therapeutics' Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Iteos Therapeutics over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Iteos Therapeutics. It is also known as Iteos Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Iteos Therapeutics' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iteos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Iteos Other Operating Expenses Regression Statistics
| Arithmetic Mean | 62,517,145 | |
| Geometric Mean | 37,026,651 | |
| Coefficient Of Variation | 109.91 | |
| Mean Deviation | 58,094,949 | |
| Median | 17,817,000 | |
| Standard Deviation | 68,709,596 | |
| Sample Variance | 4721T | |
| Range | 179.8M | |
| R-Value | 0.84 | |
| Mean Square Error | 1503.4T | |
| R-Squared | 0.70 | |
| Significance | 0.00005 | |
| Slope | 12,098,476 | |
| Total Sum of Squares | 70815.1T |
Iteos Other Operating Expenses History
About Iteos Therapeutics Financial Statements
Iteos Therapeutics shareholders use historical fundamental indicators, such as Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although Iteos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Iteos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Iteos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 188.3 M | 197.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.